Pulse Entdecken nav.journalClub Debatten Trends Forschende Zeitschriften

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

First oral GLP-1 receptor agonist approved for weight loss | Synapse

March 28, 2026

View Full Paper

First oral GLP-1 receptor agonist approved for weight loss

DADiane S. AschenbrennerJohns Hopkins University

Key Points

To evaluate the approval and usage of oral semaglutide for weight loss in patients.
Review approval status of oral semaglutide (Wegovy).
Assess warnings and adverse effects associated with the drug.
Discuss patient education on daily administration.
Oral semaglutide is the first GLP-1 receptor agonist approved for weight loss.
Warnings and adverse effects are consistent with subcutaneous semaglutide.
Patient education is crucial for effective use and absorption of the drug.

Abstract

Oral semaglutide (Wegovy) is the first oral glucagon-like peptide-1 receptor agonist to be approved for weight loss. Warnings and adverse effects remain the same for oral semaglutide as for subcutaneous semaglutide. Nurses should teach patients how to take oral semaglutide daily to promote absorption of the drug and prevent drug interactions.

KI fragen

Like

Bookmark

Share

View Full Paper

Cite This Study

Diane S. Aschenbrenner (Thu,) studied this question.

synapsesocial.com/papers/69c772058bbfbc51511e23b6 https://doi.org/https://doi.org/10.1097/ajn.0000000000000276b

KI fragen

Like

Bookmark

Share

View Full Paper